Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
about
Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpuraThe role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpuraThe potential utility of B cell-directed biologic therapy in autoimmune diseases.The kidney in thrombotic thrombocytopenic purpura.Rituximab in the treatment of autoimmune haematological disorders.A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus.Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experienceRituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child.Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndromeCase series: splenectomy: does it still play a role in the management of thrombotic thrombocytopenic purpura?Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies.Human immunodeficiency virus associated thrombotic thrombocytopenic purpura--favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy.Investigational drugs in thrombotic thrombocytopenic purpura.Novel recombinant glycosylphosphatidylinositol (GPI)-anchored ADAMTS13 and variants for assessment of anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura.Targeting B cells in severe thrombotic thrombocytopenic purpura--a road to cure?Attending rounds: microangiopathic hemolytic anemia with renal insufficiencyThrombotic microangiopathy: current knowledge and outcomes with plasma exchange.A case series of atypical presentations of thrombotic thrombocytopenic purpura.Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura.Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis.Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange.Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom.Thrombotic microangiopathy and associated renal disorders.Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports.Goodpasture's syndrome associated with thrombotic thrombocytopenic purpura secondary to an ADAMTS-13 deficit.Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases.Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura.Postoperative thrombotic thrombocytopenic purpura.How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndromeSuccessful management of thrombotic thrombocytopenic purpura in a Jehovah's Witness without plasma exchange.Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.Long-term remission of recurrent thrombotic thrombocytopenic purpura (TTP) after Rituximab in children and young adults.Thrombotic thrombocytopenic purpura as an initial presentation of systemic lupus erythematosus with acquired ADAMTS 13 antibodyHow I treat refractory thrombotic thrombocytopenic purpura.The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry.Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib.More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura.
P2860
Q24651320-29EBF511-1547-46C1-A1C4-4FF21CA57102Q28080631-6497758D-368A-4E30-98FA-FBF013A655CFQ33377109-B82C21DF-0B9D-4ACC-9D68-8AF8210F7380Q33378755-753E37B0-A31A-49E7-BAE4-B71DBB7968B8Q33378854-C7B730F0-6B26-4F09-8901-52010CA0A533Q33383190-D1C11834-6393-4BA1-9529-F540079A7692Q33389392-42EE23AD-0276-4AAF-A379-FFB5FD97E9F2Q33389561-A440EE10-28C7-4F09-89D4-BE4D1A3F4105Q33391086-AE6D35B0-8465-4633-8043-3E2210CAB552Q33391962-95B8498E-7FD2-4FE0-B04C-E1B34D8F3BDBQ33393992-2C4CB897-DD7A-4D95-98CD-2C6CC50714BDQ33394441-494A2706-1D3D-4DF3-B6A4-70C22C0ABF99Q33395696-A21AB677-3EE5-4ACE-905B-C74E309B9EE0Q33397081-391F00D4-421F-46CA-AE8F-234671A0690CQ33398799-FF3726B8-9ABA-4C1C-B136-8E461A570CD2Q33398895-C1D6CE4E-D861-4E59-883B-2B3A9CBFC00CQ33399520-D361364D-46DE-4761-A602-6602931ADDF7Q33400508-A727AA6A-74D4-4A35-A508-3D52C877F90CQ33400631-646B4B7B-AACB-4DD0-AD87-BFB75FF6210BQ33401010-B7676C58-511E-49F3-977D-AA9979DA7F02Q33401049-5894A8E2-DB70-4F03-9B4D-C864F092FC64Q33401403-AA9D903E-9B08-460A-88A8-314758972581Q33402274-21DB6AAE-BB68-4F5C-B8C2-31CD87AA9488Q33402372-CFA766A4-1AF9-42B3-ABFD-5B0910237773Q33402749-0DA34CEB-A36E-4BE6-AC3D-8F14B10022C0Q33404118-FE1DAEE9-742E-4058-B9C0-95A964CEAD2DQ33406040-BF120967-8038-43C0-A5CD-836A7698445AQ33412347-92C27E70-2A32-4B06-A5E9-EC7880A649CAQ33412350-633D9B80-7440-4ACF-9F95-A91548F86792Q33412445-0CF1414E-BDA5-4831-9AA4-FC4A90C0125AQ33414961-6CF1B914-531C-4BED-9CB7-E020AC57BED8Q33416588-C217EB83-0558-43B1-9362-12F77C1239B2Q33418352-EB68F517-AE9A-48DC-B900-8409C2B6D76AQ33419998-08078451-17CE-418F-BBC4-867776590AABQ33420591-5B287738-8D56-475B-B33E-BBE39B854FAEQ33421268-A9905879-8522-4942-87E3-DD86C3DF52F2Q33425754-707DD894-CBC9-42A1-AE08-F7F1278704B7Q33426377-D3DE1A91-2CF6-4A26-9ED2-D7A44F987439Q33429298-B8231577-EE61-485B-9377-A980581D975BQ33430243-59E7D9A5-3445-4CBE-8C6C-B279B9254306
P2860
Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Remission in acute refractory ...... n IgG antibodies to ADAMTS-13.
@ast
Remission in acute refractory ...... n IgG antibodies to ADAMTS-13.
@en
type
label
Remission in acute refractory ...... n IgG antibodies to ADAMTS-13.
@ast
Remission in acute refractory ...... n IgG antibodies to ADAMTS-13.
@en
prefLabel
Remission in acute refractory ...... n IgG antibodies to ADAMTS-13.
@ast
Remission in acute refractory ...... n IgG antibodies to ADAMTS-13.
@en
P2093
P2860
P1476
Remission in acute refractory ...... n IgG antibodies to ADAMTS-13.
@en
P2093
Hannah Cohen
Ian Mackie
Jamie Cavenagh
Marie Scully
Richard Starke
Sally Killick
Samuel J Machin
Sylvia Benjamin
P2860
P304
P356
10.1111/J.1365-2141.2006.06448.X
P407
P577
2007-02-01T00:00:00Z